Home » Stocks » FREQ

Frequency Therapeutics, Inc. (FREQ)

Stock Price: $10.24 USD -0.27 (-2.57%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 359.64M
Revenue (ttm) 36.98M
Net Income (ttm) -26.51M
Shares Out 34.22M
EPS (ttm) -10.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $10.24
Previous Close $10.51
Change ($) -0.27
Change (%) -2.57%
Day's Open 10.52
Day's Range 9.83 - 10.58
Day's Volume 584,902
52-Week Range 7.34 - 58.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 hour ago - Zacks Investment Research

Their stocks have collapsed. But they could still be huge winners.

Other stocks mentioned: AXSM, TRIL
1 week ago - The Motley Fool

A risky path lies ahead for the clinical-stage biotech, which saw disappointing results for FX-322 in March 2021. Can management learn from its mistakes?

2 weeks ago - The Motley Fool

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused ...

3 weeks ago - Business Wire

These drugmaker stocks may have been hammered down to bargain-bin prices.

Other stocks mentioned: SLDB, SRRK
3 weeks ago - The Motley Fool

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

3 weeks ago - Business Wire

NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ). Such investors are ad...

1 month ago - PRNewsWire

LOS ANGELES, April 2, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Frequency Therapeutics,...

1 month ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $FREQ #FREQ--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc.

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - March 31, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ). Such i...

1 month ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FREQ #FREQ--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc.

1 month ago - Business Wire

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of 0.00% and -2.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...

1 month ago - Zacks Investment Research

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

1 month ago - Business Wire

Frequency Therapeutics Inc. (NASDAQ: FREQ) shares were absolutely crushed in Tuesday's session.

1 month ago - 24/7 Wall Street

Frequency Therapeutics Inc. (NASDAQ: FREQ) stock imploded Tuesday amid the company's announcement that its interim FX-322 Phase 2a results showed that four weekly injections did not demonstrate improvem...

1 month ago - Benzinga

The company announced disappointing results from a phase 2a study.

1 month ago - The Motley Fool

Frequency Therapeutics Inc (NASDAQ: FREQ) stock plunges in the premarket after reporting topline day-90 data from its Phase 2a study (FX-322-202) evaluating the company's lead product candidate FX-322 i...

1 month ago - Benzinga

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly i...

1 month ago - Business Wire

Frequency Therapeutics, Inc. (FREQ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

Investors need to pay close attention to Frequency Therapeutics (FREQ) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Frequency Therapeutics Inc (NASDAQ: FREQ) has announced the publication of its lead candidate FX-322 Phase 1/2 study results in Otology & Neurotology. The data was initially announced in April 2019.

2 months ago - Benzinga

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

2 months ago - Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

2 months ago - Business Wire

Vir Biotechnology (NASDAQ: VIR) shares are trading lower Wednesday after JPMorgan downgraded the stock from Neutral to Underweight and announced a price target of $30 per share. Vir Biotechnology is a c...

Other stocks mentioned: ANTM, VIR
3 months ago - Benzinga

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

3 months ago - Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

4 months ago - Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

4 months ago - Business Wire

Frequency Therapeutics (FREQ) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

Find Strong Stocks with this New Analyst Coverage Screener

Other stocks mentioned: ODP, XPER
4 months ago - Zacks Investment Research

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

5 months ago - Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

5 months ago - Business Wire

Frequency Therapeutics is using novel progenitor cell stimulating technology to regrow hair cells in the ear and improve hearing loss in patients. Progenitor cells are found all throughout the body, so ...

5 months ago - Seeking Alpha

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...

6 months ago - Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by ...

7 months ago - Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by ...

7 months ago - Business Wire

Frequency Therapeutics Has A Strong Scientific Rationale And An Upcoming Binary Catalyst

7 months ago - Seeking Alpha

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

7 months ago - Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

7 months ago - Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

8 months ago - Business Wire

These strong stocks to buy benefited from atypical and big insider buying activity over the past few weeks. The post 5 Stocks to Buy Because of Heavy Insider Buying in July appeared first on InvestorPl...

Other stocks mentioned: CASI, FDX, GES, LEVI
9 months ago - InvestorPlace

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: FDX, GES
9 months ago - Benzinga

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: APLT, GRBK, KELYA
9 months ago - Zacks Investment Research

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

9 months ago - Business Wire

Frequency Therapeutics: FX-322 Top Line Data From Exploratory Study Proves Promising

11 months ago - Seeking Alpha

While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.

Other stocks mentioned: APRE, VIE, VIR
1 year ago - The Motley Fool

Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares in the open market?

Other stocks mentioned: APRE, VIE
1 year ago - The Motley Fool

Frequency Therapeutics (NASDAQ: FREQ) made its public debut Thursday morning, opening at $11.20 after being priced at $14 per share.

1 year ago - Benzinga

About FREQ

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of... [Read more...]

Industry
Biotechnology
IPO Date
Oct 3, 2019
Stock Exchange
NASDAQ
Ticker Symbol
FREQ
Full Company Profile

Financial Performance

In 2020, FREQ's revenue was $36.98 million, an increase of 27.76% compared to the previous year's $28.95 million. Losses were -$26.51 million, 41.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FREQ stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 124.61% from the latest price.

Price Target
$23.00
(124.61% upside)
Analyst Consensus: Buy